ArticleScientific reports2025
The specific contributions of factor H and factor I in controlling fluid phase activation of the alternative complement pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dual roles of complement in ulcerative colitis: insights from clinical studies and animal research.European journal of medical research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immediate defense provided by the alternative complement pathway (AP) is under constant control by fluid phase regulators, factor H (FH) and factor I (FI), to prevent nonessential activation. Removal of either FI or FH from serum results in spontaneous AP activation, although the extent of activation caused by separate removal of each regulator has not been compared. In purified protein reactions with < 25% normal FH levels, additions of 6-100% normal FI levels, did not reduce C3a, Ba or FB cleavage. In reactions with 100% FH: C3a was not generated; Ba and FB cleavage was 3-fold lower; and C3 inactivation increased 2-fold as FI concentrations doubled. In reactions with 100% FI, FH levels ≥ 25% reduced C3a and Ba levels. AP activation levels were also compared in FI-depleted and FH-depleted serum. After magnesium addition to FI-depleted serum, C3a remained unchanged and Ba increased 3-fold, whereas in FH-depleted serum, C3a increased 13-fold and Ba increased 20-fold. Addition of 100% FI protein to FI-depleted serum did not change C3a and Ba, whereas, 100% FH added to FH-depleted serum prevented all activation. We conclude that normal levels of FH are sufficient to compensate for FI deficiencies and prevent unnecessary fluid phase AP activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.